medigraphic.com
ISSN 0188-9796 (Print)

2007, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2007; 15 (1)

Substitutive hormone therapy with testosterone in the aging male

Porias CHL, Lamm WL

Language: Spanish
References: 46
Page: 8-18
PDF size: 171.44 Kb.


ABSTRACT

Testosterone therapy in the aging male is now possible. Although the experience of sex hormone substitution is not as those in women, recent data are promising for the future. Once the diagnosis has been made, the testosterone therapy in different pharmacological presentations may improve sexual, physical and mental disturbances but also the quality of life reached by this treatment is a definitive goal. It is not as simple as taking one of the pharmacological products; it is important to make a good prescription assuming the individual characteristics of each patient. The initial evaluation is essential since from these data a comparison is possible during and after the time of therapy. The metabolic, bone, cardiovascular and sexual benefits has been analyzed and a favorable result of the testosterone therapy are supported against the risks that may be the counterpart. If the possible risk are provide for and a caution follow up is well designed (for example prostate antigen is measured before and every three month) more benefits will appear during the treatment. We know that the aging male is increasing in the all world population so every effort to improve the life quality is an important issue. The pharmacological presentations will grow in a easier way to prescribe. By the time the only oral product that may avoid the absorption direct to the liver is the undecanoate that goes directly into de lymph circulation. The dermic preparations started with a big patch put over the scrotum and have changed to other kind of patches and now a gel is available in some countries. So in the near future the men will have a lot of options and perhaps not forget that he has the same right to be treated to live better in a world in which the longevity will be the common characteristics.


REFERENCES

  1. Lunenfeld B. Editorial. The aging male 1998; 1: 1-5.

  2. Gambineri A. Pasquali R. Testosterone therapy in men: Clinical and pharmacological perspectives. J Endocrinol Invest 2000; 23: 196: 214.

  3. Summary from de 2nd annual Andropause Consensus Meeting 2001. The Endocrine Society ed. Cunningham GR et al.

  4. Nieschlag E et al. Investigation, treatment and monitoring of late onset hypogonadism in males ISA ISSAM and EUA recommendations. Int Journ of Andrology 2005; 28: 125-127.

  5. Morales A. Andropause: facts fictions and controversies. The Aging Male 2004; 7: 297-303.

  6. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilatation and response to sildenafil in patients with erectile disfunction. Clin Endocrinol (Oxf) 2003; 58: 632-638.

  7. Marin P, Arver S. Androgens and abdominal obesity. Balliers Clin Endocrinol Metab 1998; 12(3): 441-451.

  8. Wild S, Pierpoint T, Mc Keighe P, Jacobs H. Cardiovascular disease in women with polycistyc ovary syndrome at long term follow up a retrospective cohort study. Clin Endocrinol 2002; 52: 1365-2265.

  9. Christiansen K. Behavioral correlates of testosterone chapter 3. In: Testosterone action deficiency substitution. Ed. Nieschlag E, Behre HM (Springer) 1999: 107-142.

  10. Tan RS, Pu SJ. The andropause and memory loss: Is there a link between androgen decline and dementia in the aging male? Asian J Androl 2001; 3(3): 169-174.

  11. Nadell J. Pelliosis Hepatis, 12 cases associated with oral androgen therapy. Arch Pathol Lab Med 1977; 101: 405-410.

  12. Hong JH, TY AHN. Oral testosterone replacement in Korean patients with. PADAM Aging Male 2002; 5: 52-56.

  13. Gooren L J. A ten years safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212-215.

  14. Geere G, Jones J, Atherden SM, Grant DB. Plasma androgens after a single oral dose of testosterone undecanoate. Archives of Disease in Childhood 1980; 55: 218-220.

  15. Behre HM, Nieschlag E. Testosterone buciclate in hypogonadal men pharmaco-kinetiks and pharmaco-dynamics of a new long acting testosterone ester. J Clin Endocrinol Metab 1992; 75: 1204-1210.

  16. Schubert M, Minneman T, Hübler D. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. JCEM 2004: 89: 5429-5434.

  17. Meikle AW, Hoffman MD. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU 2004; 93: 1464-1474.

  18. Rolf C, Kemper S, Lemmnitz F, Eickenberg U, Nieschlag E. Interpersonal testosterone transfer after topical applications of a newly developed testosterone gel preparation. Clin Endocrinol 2002; 56: 637-641.

  19. Jockenhövel F, Vogel E, Kreutzer M, Reinhardt W. Pharmacokinetics and pharmacodinamics of subcutaneous testosterone implants in men. Clin Endocrinol 1996; 45: 262-262.

  20. Anderson JK, Faulkner S, Cranor C, Briley J, Gevirtz F, Robert S. Andopause: Knowledge and perceptions among the general public and health care professionals. J Gerantol A Biol Sci Med Sci 2002; 57: M793-M796.

  21. Morley JE, Charlton E, Patrick P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49(9): 1239-1242.

  22. Porias HL, Lamm L et al. Estudio del hipoandrogenismo relativo en adultos, mediante la aplicación de un cuestionario y su correlación con las concentraciones de hormonas masculinas como base para el diagnóstico de andropausia. Climaterio 2003; 34: 157-165.

  23. Bashin S, Gabelnick HL. Testosterone therapy in adult men with androgen deficiency syndromes. An endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.

  24. Ebert T. Clinical experiences with testosterone therapy: prostate safety. The Aging Male 2004; 7: 304-311.

  25. Matsumoto AM, Sandblom RE, Schoene RB et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985; 22: 713-721.

  26. Santamaria JD, Prior JC, Fleetham JA. Reversible reproductive dysfunction in men with obstructive sleep apnea. Clin Endocrinol (Oxf) 1988; 28: 461-470.

  27. Barrett-Connor E, Khaw KT. Endogenous sex hormones levels and cardiovascular disease in men. Circulation 1988; 78: 530-543.

  28. Simon D, Prezzini P, Barret-Conoor E, Roger M, Saint Paul M et al. Population variation in age-related decline in male salivary testosterone. Am Jour of Epidemiol 1992; 7: 738-91.

  29. Rosano GM, Leonardo F, Pagnotta P. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-1670.

  30. Von Eckerstein A. l Testosterone and cardiovascular disease. In: Nieschlag E and Behre HM (eds). Testosterone action deficiency and substitution 3nd edn Cambridge University press 2004: 297-331.

  31. Phillips GB. Sex hormones risk factor and cardiovascular disease. Am J Med 1978; 65: 7-11.

  32. Marin P, H Kvist G, Lindstedt L, Sjostrom P. The effects of testosterone on body composition and metabol. In middle aged men. In J Obesity 1992; 16: 991-997.

  33. Iranmaresh A. Unequal impact of age, percentage body fat and serum testosterone concentrations, IGF I and IGF binding protein responses to a three day intravenous growth hormone –releasing hormone pulsatil infusion in men. Eur J Endocrinol 1998; 139: 59-71.

  34. 34 Bhasin S. Testosterone replacement increases fat free mass and muscle size in hypogondal men. JCEM 1997; 82: 407-413.

  35. Luukkaa V. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83: 3242-3246.

  36. Kapoor D, Malkint CJ, Channert KS, Jones TH. Androgen, insulin resistance and vascular disease in men. Clin Endocrinology 2005; 63: 239-242.

  37. Boyanov MA. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The Aging Male 2003; 1: 1-7.

  38. Jee-Young OH, Barrett-Connor E, Wedick NE, Wingard DL. Rancho Bernardo Study Endogenous sex hormones and development of type 2 diabetes in older men and women. The Rancho Bernardo Study. Diabetes Care 2002; 25: 55-60.

  39. Klentze M. (Klentze Institute of anti-Aging, Munich, Germany) Testosterone: The male hormonal connection. Treating diabetes and heart disease www.worldhealth.net/pdf/bookstore/thera6_ch7.pdf

  40. Abate N, Haffner SM, Garg A et al. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 87: 4522-4527.

  41. Orwoll ES, Klein RF. Osteoporosis in men. Endocrine Rev 1995; 16: 87-116.

  42. Riggs BL, Khosla S, Melton L J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and II in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763-773.

  43. Katzenelson L et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358-4365.

  44. Behre HM, Kliesch S, Leifke E, Link T, Nieschla E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 8: 2386-2390.

  45. Amin S, Zhang Y, Swin CT, Evans SR, Hannan Mt et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from Framingham study. Ann Intern Med 2000; 133: 951-963.

  46. Orwoll ES, Stribrska I, Ramsey EE, Keenan EJ. Androgen receptor in osteoblast like cell lines. Calcif Tissue Int 1991; 49: 183-187.




2020     |     www.medigraphic.com